Skip to main content

Table 3 Effectiveness of Palbociclib-based treatment in different treatment-line settings

From: Palbociclib plus endocrine therapy in hormone receptor-positive and HER2 negative metastatic breast cancer: a multicenter real-world study in the northwest of China

 

All patients

(n = 211)

1st line

(n = 85)

2nd line

(n = 78)

≥ 3rd line

(n = 48)

Best response

    

 Partial response

46(21.8)

23(27.1)

17(21.8)

6(12.5)

 Stable disease

145(68.7)

58(68.2)

53(67.9)

34(70.8)

 Progressive disease

20(9.5)

4(4.7)

8(10.3)

8(16.7)

Objective response rate

46(21.8)

23(27.1)

17(21.8)

6(12.5)

Disease control rate

191(90.5)

81(95.3)

70(89.7)

40(83.3)

Progression-free rate

    

 6 months

136(64.5)

59(69.4)

43(55.1)

34(70.8)

 12 months

65(30.8)

33(38.8)

21(26.9)

11(22.9)

Survival outcome (months)

    

 Median PFS (95% CI)

12.2(10.1–14.3)

14.5(11.1–17.9)

10.6(4.1–17.1)

8.7(6.8–10.7)

  1. Values are presented as number (%) unless otherwise indicated. CI, confidence interval